Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAvingtrans Regulatory News (AVG)

Share Price Information for Avingtrans (AVG)

Share Price is delayed by 15 minutes
Get Live Data
670.00    40.00 (6.35%)
Bid:
660.00
Ask:
680.00
Spread: 20.00 (3.03%)
Market Cap: £225.27m
AVG Live PriceLast checked at - London Stock Exchange

Intraday Avingtrans Share Chart

Update on Return of funds to Shareholders

30 Jun 2016 07:00

RNS Number : 7239C
Avingtrans PLC
30 June 2016
 

30 June 2016

Avingtrans Plc

("Avingtrans" or the "Company" or the "Group")

 

Update on Return of funds to Shareholders following disposal of Aerospace Division

 

Avingtrans (AIM:AVG), a manufacturer of critical components and associated services to the global energy and medical sectors, is pleased to provide an update to shareholders on the proposals for the return of capital to shareholders following the disposal of the Aerospace Division.

 

As the Company announced on 27 May 2016, following the disposal of the Aerospace Division, the Company had net cash in excess of £47 million. The Board is now pleased to announce that it intends to return almost £28 million to shareholders by way of a Tender Offer ("the Offer"), representing 100p for each ordinary share in issue. The Company currently has 27,754,564 ordinary shares in issue.

 

The Board expects to announce its final results for the year ended 31 May 2016 during September 2016 and at the same time post a circular to shareholders setting out further terms of the Offer, and also seeking the necessary shareholder approvals.

 

The balance of the net proceeds will be used to pursue the Groups new strategy to invest in the Energy and Medical markets served by its Metalcraft and Maloney Metalcraft businesses, and more specifically to strengthen Metalcraft's position in the nuclear sector and to pursue other related opportunities in the engineering sector.

 

Steve McQuillan, Chief Executive Officer of Avingtrans plc, commented "I am pleased to be able to provide more detail on the return of substantial value to shareholders while also reiterating our intention to make additional investment and acquisitions in the Energy and Medical businesses. The Board believes there are several exciting prospects which have the potential to deliver significant further value for shareholders."

 

 

Enquiries:

 

Avingtrans plc

Steve McQuillan, Chief Executive Officer

Stephen King, Chief Financial Officer

 

Tel: 01159 499 020

Numis

Richard Thomas (Corporate Finance and Nominated Adviser)

Tom Ballard (Corporate Broking)

 

Tel: 0207 260 1000

Newgate (Financial PR)

Adam Lloyd

Ed Treadwell

Tel: 020 7653 9850

 

 

 

 

About Avingtrans

 

Avingtrans plc is engaged in the provision of highly engineered components, systems and services to the energy, medical and traffic management industries worldwide.

 

Energy and medical, engaged in the design and manufacture of safety critical equipment for the energy, medical, science and research communities, including oil and gas extraction and processing equipment, nuclear process plant, machined and fabricated pressure and vacuum vessels and components. Also, design and manufacture of fabricated poles and cabinets for roadside safety cameras and rail track signalling.

 

The strategy of the group, is to "buy and build" in regulated engineering niche markets, where we can see potential consolidation opportunities, which can lead to significantly increased shareholder value over the medium to long term

 

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCFKLLLQQFFBBL
Date   Source Headline
10th Jul 202611:56 amRNSResult of Placing
10th Jul 20269:33 amRNSClose of Accelerated Bookbuild
10th Jul 20267:00 amRNSLaunch of Proposed Placing
24th Jun 20267:00 amRNSTrading Update and Notice of Results
19th May 202610:20 amRNSHolding(s) in Company
14th May 202612:26 pmRNSHolding(s) in Company
12th May 20267:00 amRNSAdaptix receives CE Certification
6th May 20264:28 pmRNSHolding(s) in Company
30th Apr 20262:42 pmRNSHolding(s) in Company
30th Apr 20262:41 pmRNSExercise of Options & TVR
24th Apr 20262:54 pmRNSHolding(s) in Company
16th Apr 20267:00 amRNSStrong Nuclear Orders for Avingtrans
26th Mar 20267:00 amRNS-RScientific Magnetics Ships 20th Quantum Magnet
4th Mar 20267:00 amRNSHolding(s) in Company
25th Feb 20267:00 amRNSInterim Results
12th Feb 202611:49 amRNSHolding(s) in Company
6th Feb 202610:24 amRNSHolding(s) in Company
27th Jan 20265:42 pmRNSExercise of Options & TVR
21st Jan 20267:00 amRNSTrading Update and Notice of Results
12th Jan 20265:13 pmRNSIssue of Share Options
12th Jan 20267:00 amRNS-RMedical & Industrial Imaging Division Appointment
8th Dec 20252:34 pmRNSNotification of Major Holdings
27th Nov 20251:59 pmRNSResult of AGM - Board Appointment
14th Nov 20258:38 amRNSExercise of Options & PDMR Dealings
10th Nov 20257:00 amRNSAdaptix receives FDA 510(K) clearance
1st Oct 20254:52 pmRNSExercise of Options & Total Voting Rights
1st Oct 20253:32 pmRNSHolding(s) in Company
29th Sep 20257:00 amRNSAppointment of Medical Division CEO
24th Sep 20257:00 amRNSPreliminary results for the year ended 31 May 2025
11th Sep 20258:00 amRNSHolding(s) in Company
2nd Sep 20257:00 amRNSHayward Tyler Secures $16m Nuclear Contracts
28th Aug 20257:00 amRNSBooth Industries secures £8.5m HS2 & TfL contracts
25th Jun 20257:00 amRNSTrading Update and Notice of Results
28th May 20257:00 amRNSTrading Update
26th Feb 20257:00 amRNSInterim Results
13th Feb 20257:00 amRNSBooth Industries secures £4.5m Contract
16th Jan 20257:00 amRNSTrading Update & Notice of Results
21st Nov 20244:09 pmRNSResult of AGM
24th Oct 20249:07 amRNSHolding(s) in Company
25th Sep 20247:00 amRNSPreliminary results for the year ended 31 May 2024
3rd Jul 20247:00 amRNSPDMR Dealings
19th Jun 20247:00 amRNSTrading Update and Notice of Results
26th Mar 202411:15 amRNSPDMR Dealings
21st Mar 20245:15 pmRNSExercise of Options, PDMR Dealings & TVR
20th Mar 20243:39 pmRNSHolding(s) in Company
4th Mar 20246:10 pmRNSPDMR Dealings
28th Feb 20247:00 amRNSInterim Results
18th Jan 20247:00 amRNSTrading Update and Notice of Results
15th Dec 20233:00 pmRNSExercise of Options & TVR
4th Dec 20237:00 amRNSMagnetica Limited appoints US distributor

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.